| Literature DB >> 35110735 |
J Joseph Melenhorst1,2,3,4,5, Gregory M Chen6, Meng Wang7,8,9, David L Porter9,10, Changya Chen11,12, McKensie A Collins7,8,9,13, Peng Gao11,12, Shovik Bandyopadhyay13, Hongxing Sun7,8,9, Ziran Zhao7,8,9, Stefan Lundh7,8,9, Iulian Pruteanu-Malinici14, Christopher L Nobles15, Sayantan Maji7,8,9, Noelle V Frey9, Saar I Gill9, Lifeng Tian7,9, Irina Kulikovskaya7,8,9, Minnal Gupta7,8,9, David E Ambrose7,8,9, Megan M Davis7,8,9, Joseph A Fraietta7,8,9,15, Jennifer L Brogdon14, Regina M Young7,8,9, Anne Chew7,8,9, Bruce L Levine7,8,9, Donald L Siegel7,8,16, Cécile Alanio17,18,19, E John Wherry17,18,19, Frederic D Bushman15, Simon F Lacey7,8,9, Kai Tan20,21,22,23,24, Carl H June25,26,27,28,29.
Abstract
The adoptive transfer of T lymphocytes reprogrammed to target tumour cells has demonstrated potential for treatment of various cancers1-7. However, little is known about the long-term potential and clonal stability of the infused cells. Here we studied long-lasting CD19-redirected chimeric antigen receptor (CAR) T cells in two patients with chronic lymphocytic leukaemia1-4 who achieved a complete remission in 2010. CAR T cells remained detectable more than ten years after infusion, with sustained remission in both patients. Notably, a highly activated CD4+ population emerged in both patients, dominating the CAR T cell population at the later time points. This transition was reflected in the stabilization of the clonal make-up of CAR T cells with a repertoire dominated by a small number of clones. Single-cell profiling demonstrated that these long-persisting CD4+ CAR T cells exhibited cytotoxic characteristics along with ongoing functional activation and proliferation. In addition, longitudinal profiling revealed a population of gamma delta CAR T cells that prominently expanded in one patient concomitant with CD8+ CAR T cells during the initial response phase. Our identification and characterization of these unexpected CAR T cell populations provide novel insight into the CAR T cell characteristics associated with anti-cancer response and long-term remission in leukaemia.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35110735 PMCID: PMC9166916 DOI: 10.1038/s41586-021-04390-6
Source DB: PubMed Journal: Nature ISSN: 0028-0836 Impact factor: 69.504